- Home
- NFGC vs CDNA Comparison
NFGC vs CDNA Comparison
Compare NFGC & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NFGC | CDNA |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.8M | 1.0B |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NFGC | CDNA |
|---|---|---|
| Price | $2.96 | $18.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $5.00 | ★ $27.33 |
| AVG Volume (30 Days) | ★ 2.0M | 612.3K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $12.18 |
| Revenue Next Year | $1,887.56 | $10.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $0.93 | $10.96 |
| 52 Week High | $3.59 | $22.61 |
Technical Indicators
Market Signals| Indicator | NFGC | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 44.64 |
| Support Level | $2.86 | $18.30 |
| Resistance Level | $3.24 | $20.74 |
| Average True Range (ATR) | 0.17 | 1.05 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 72.92 | 43.16 |
Price Performance
Historical ComparisonAbout NFGC New Found Gold Corp
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Company's exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.